The short answer is yes—starting July 1 2026 Montana permits the use of mifepristone‑misoprostol for medication abortions up to 12 weeks of gestation, provided the prescriber follows the newly enacted registration, counseling, and reporting requirements. This change reverses the 2024 temporary ban and aligns the state with the federal FDA approval of the abortion pill, while still limiting use after the first trimester and imposing strict telehealth safeguards.
Post‑2026 Legislative Framework
Montana’s “Reproductive Health Access Act” (Mont. Code Ann. §§ 51‑1‑101 to ‑108, 2026) repealed the 2024 prohibition and introduced a licensing system for physicians and advanced practice clinicians who prescribe the pill. The law requires a written informed‑consent form, a 24‑hour waiting period, and mandatory reporting of each medication abortion to the state health department. It also prohibits the distribution of the pills through mail‑order pharmacies that are not registered in Montana.
Key Provisions Affecting Medication Abortion
- Gestational limit – The pill is authorized only for pregnancies confirmed to be 12 weeks or less, as verified by ultrasonography or reliable dating methods.
- Provider qualifications – Physicians, nurse practitioners, and physician assistants may prescribe after completing a state‑approved training module on medication abortion.
- Telehealth restrictions – Remote prescribing is allowed only when the patient has had an in‑person exam within the preceding 30 days; otherwise, a face‑to‑face visit is mandatory.
- Conscientious‑objector clause – Clinicians who object on moral grounds are not forced to prescribe, but must refer patients to a willing provider within 24 hours.
- Penalties – Unregistered dispensing or prescribing beyond the gestational limit carries a Class A misdemeanor and possible loss of medical licensure.
What This Means for Patients and Providers
For patients, the law restores access to a safe, FDA‑approved option for early‑term abortion, but it also adds procedural steps that can delay care. Providers must navigate licensing, documentation, and reporting duties, which may increase administrative burdens but also standardize practice across the state. Legal scholars note that Montana’s approach reflects a “middle‑ground” model: it respects reproductive autonomy while imposing state‑level safeguards (see Mont. Rev. Stat. 2026 ed.).
Frequently Asked Questions
How does Montana’s law differ from the federal FDA regulations?
The FDA permits the pill up to 10 weeks nationwide, whereas Montana extends the limit to 12 weeks and adds state‑specific consent, waiting‑period, and reporting requirements.
Can minors obtain the abortion pill in Montana?
Yes, minors may receive the medication if a parent or legal guardian signs the consent form, or if a judge issues a waiver based on the minor’s best‑interest claim, as outlined in § 51‑1‑105.
Are out‑of‑state telemedicine services still prohibited?
Only if the patient has not had an in‑person exam in the last 30 days. After that window, a Montana‑licensed provider must conduct the evaluation before prescribing.
What happens if a provider fails to report a medication abortion?
Failure to file the required report within 48 hours subjects the provider to a Class A misdemeanor and possible suspension of their medical license.
Does the law affect the availability of over‑the‑counter mifepristone?
No. The act requires all dispensed medication to come from a registered pharmacy; over‑the‑counter sales are not permitted.
These provisions collectively shape the practical reality of medication abortion in Montana after the 2026 reforms